Calumet announced that the company has filed a prospectus supplement with the U.S. SEC establishing an at-the-market equity offering program under which it may issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $65M. Calumet intends to use the net proceeds from the ATM Program for general corporate purposes, which may include, among other things, repayment of indebtedness, working capital and capital expenditures. BMO Capital Markets is acting as sales agent.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Specialty Products sees Q4 adjusted EBITDA $45M-$60M
- Calumet Specialty price target raised to $33 from $25 at H.C. Wainwright
- Calumet’s MRL reports loan guarantee agreement with U.S. DOE
- Unusually active option classes on open January 13th
- Calumet Specialty Products call volume above normal and directionally bullish